Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 509-515

  Bruland, Øyvind S ^a   Høifødt, Hanne ^a   Hall, Kirsten Sundby ^a   Smeland, Sigbjørn ^a   Fodstad, Øystein ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTINEOPLASTIC AGENT; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER CELL; CANCER GRADING; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; LEG AMPUTATION; MALE; MICROMETASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TUMOR LOCALIZATION; ADOLESCENT; BONE MARROW CANCER; BONE TUMOR; LIMB; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SECONDARY;

ADOLESCENT; ADULT; BONE MARROW NEOPLASMS; BONE NEOPLASMS; CHILD; EXTREMITIES; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; MALE; MIDDLE AGED; OSTEOSARCOMA;

EID: 77953664491     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_30     Document Type: Conference Paper

References (39)

1. Malawer MM, Helman LJ, O'Sullivan B. Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer - Principles&Practice of Oncolog. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005:1638-1686.
2. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33(11):1725-1731.
3. Huvos AG. Osteogenic sarcoma. In: Huvos AG, ed. one Tumors. Diagnosis, treatment and prognosis. Philadelphia: WB Saunders; 1991:85-155.
4. Dahlin D, Unni K. Osteogenic sarcoma of bone and its important recognizable varieties. Am J Surg Pathol.. 1977;1:61-72.
5. Sæter G, Bruland øS, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma The Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol. 1996;35(Suppl 8):129-134.
6. Aksnes LH, Hall KS, Folleraas G, et al. Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience. Acta Oncol. 2006;45(1):38-46.
7. Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb. 1955;1: 79-111.
8. Tournade MF, Com-Nougué C, Voûte PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol. 1993;11(6):1014-1023.
9. Larson S, Stock W. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol. 2008;15(4):400-407.
10. Mansi JL, Gogas H, Bliss JM, et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet.. 1999;354(9174):197-202.
11. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91(13):1113-1124.
12. Wiedswang G, Borgen E, Kaaresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21:3469-3478.
13. Pantel K, Muller V, Auer M, et al. Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res. 2003;9(17):6326-6334.
14. Brunsvig PF, Flatmark K, Aamdal S, et al. Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer. 2008;61(2):170-176.
15. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793-802.
16. Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11(13):4666-4673.
17. Carlson MJ. Circulating sarcoma cells: the incidence of 3thymidine labeling in the peripheral blood of normal and sarcoma patients. Thesis - University of Minnesota 1978.
18. Kaiser TE. The detection of tritiated thymidine labeled cells in the peripheral blood of sarcoma patients and the nature of these cells bearing prognostic significance for sarcoma patients. Thesis - University of Minnesota 1985.
19. Foss PO, Messelt OT, Efskind J. Isolation of cancer cells from blood and thoracic duct lymph by filtration. Surgery. 1963;53(2):241-246.
20. Foss PO, Brennhovd IO, Messelt OT, Efskind J, Liverud K. Invasion of tumor cells into the bloodstream caused by palpation or biopsy of the tumor. Surgery. 1966;59(5):691-695.
21. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer. 2000;36(13):1681-1694.
22. Taback B, Chan AD, Kuo CT, et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: Correlation with clinical stage of disease. Cancer Res. 2001;61:8845-8850.
23. Flatmark K, Bjørnland K, Johannessen HO, et al. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res. 2002;8(2):444-449.
24. Faye R, Aamdal S, Høifødt HK, et al. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res.2004;15:4134-4149.
25. Bruland øS, Fodstad ø, Funderud S, Pihl A. New monoclonal antibodies specific for human sarcomas. Int J Cancer. 1986;38:27-31.
26. Bruland øS, Fodstad ø, Stenwig E, Pihl A. Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res. 1988;48:5302-5309.
27. Bruland øS, Fodstad ø, Skretting A, Pihl A. Selective radiolocalization of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts. Br J Cancer. 1987;56:21-25.
28. Bruland øS, Aas M, Fodstad ø, et al. Immunoscintigraphy of bone sarcomas. Results in five patients. Eur J Cancer. 1994;30:1484-1489.
29. Morgan AC Jr, Galloway DR, Reisfeld RA. Production and characterization of a monoclonal antibody to a melanoma specific glycoprotein. Hybridoma. 1981;1:27-36.
30. Godal A, Bruland OS, Haug E, Aas M, Fodstad O. Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells. Br J Cancer. 1986;53:839-841.
31. Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. J Clin Oncol. 1998;16:1707-1711.
32. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatric Hematol/Oncol. 2001;23/2:99-104.
33. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapse associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol. 2003;21(1):85-91.
34. Tveito S, Maelandsmo GM, Hoifodt HK, Rasmussen H, Fodstad ø. Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis. 2007;24(5):317-327.
35. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in highgrade osteosarcoma in relation to clinical outcome. N Engl J Med. 1995;333:1380-1385.
36. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;5442/9:5442-5453.
37. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003;21(3):536-542.
38. Valabrega G, Fagioloi F, Corso S, et al. ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. Br J Cancer. 2003;88:396-400.
39. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol. 2004;15:151-160.